Review of tadalafil in the treatment of erectile dysfunction

Expert Opinion on Pharmacotherapy

Volumn 4, Issue 11, 2003, Pages 2049-2056

  Meuleman, Eric J H ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Erectile dysfunction; Phosphodiesterase type 5 inhibition; Tadalafil; Treatment

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BENDROFLUMETHIAZIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARBAMAZEPINE; CLARITHROMYCIN; CYTOCHROME P450 INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ERYTHROMYCIN; ITRACONAZOLE; KETOCONAZOLE; METOPROLOL; NITRIC ACID DERIVATIVE; NITRIC OXIDE; PHENOBARBITAL; PHENYTOIN; PHOSPHODIESTERASE INHIBITOR; PROTEINASE INHIBITOR; RIFAMPICIN; RITONAVIR; SAQUINAVIR; SILDENAFIL; TADALAFIL; THIAZIDE DIURETIC AGENT; UNINDEXED DRUG; VARDENAFIL;

AREA UNDER THE CURVE; CLINICAL TRIAL; CONJUNCTIVAL HYPEREMIA; DISTRIBUTION VOLUME; DOSE KIDNEY FUNCTION RELATION; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG ALCOHOL INTERACTION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG MARKETING; DRUG METABOLISM; DRUG POTENCY; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG SELECTIVITY; DRUG TARGETING; DRUG TOLERABILITY; DYSPEPSIA; EMBRYOTOXICITY; ERECTILE DYSFUNCTION; EYE PAIN; EYELID EDEMA; FETOTOXICITY; FOOD DRUG INTERACTION; HEADACHE; HUMAN; MALE; MULTIPLE DRUG DOSE; NONHUMAN; REVIEW; SINGLE DRUG DOSE; STRUCTURE ACTIVITY RELATION; TERATOGENICITY;

AGED; CARBOLINES; DRUG INTERACTIONS; HUMANS; IMPOTENCE; MALE; PATIENT COMPLIANCE; PHOSPHODIESTERASE INHIBITORS;

EID: 0242407425     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.4.11.2049     Document Type: Review

References (53)

1. AYTA IA, MCKINLAY JB, KRANE RJ: The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int. (1999) 84(1):50-56.
2. FUGL-MEYER AR, LODNERT G, BRANHOLM IB, FUGL-MEYER KS: On life satisfaction in male erectile dysfunction. Int. J. Impotence Res. (1997) 9:141-148.
3. STOLK EA, BUSSCHBACH JJV: Are patients and the general public like-minded about the effect of erectile dysfunction on quality of life? Urology (2003) 61:810-815.
4. FELDMAN HA, GOLDSTEIN I, HATZICRRISTOU DG, KRANE RJ, MCKINLAY JB: Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Ageing Study. J. Urol. (1994) 151:54-61.
5. MASUMORI N, TSUKAMOTO T, KUMAMOTO Y et al.: Decline of sexual function with age in Japanese men compared with American men results of two community-based studies. Urology (1999) 54:335-344.
6. MARUMO K, MURAI M: Ageing and erectile dysfunction: the role of ageing and concomitant chronic illness. Int. J. Urol. (2001) 8(8):S50-S57.
7. MEULEMAN EJ, DONKERS LH, ROBERTSON C, KEECH M, BOYLE P, KIEMENEY LA: ED: prevalence and effect on the quality of life; Boxmeer study. Ned. Tijdschr. Geneeskd. (2001) 145(12):576-581.
8. BRAUN M, WASSMER G, KLOTZ T, REIFENRATH B, MATHERS M ENGELMANN U: Epidemiology of ED: results of the 'Cologne Male Survey'. Int. J. Impot. Res. (2000) 12:305-311.
9. MULLIGAN T, RETCHIN SM, CHINCHILLI VM, BETINGER CB: The role of ageing and chronic disease in sexual dysfunction. J. Am. Geriatr. Soc. (1988) 36:520-524.
10. MEULEMAN EJ: Prevalence of erectile dysfunction: need for treatment? Int. J. Impot. Res. (2002) 14(Suppl. 1):S22-S28.
11. SEFTEL AD: ED in the elderly: epidemiology, aetiology and approaches to treatment. J. Urol. (2003) 169:1999-2007.
12. HATZICHRISTOU DG, APOSTOLIDIS A, TZORTZIS V, LOANNIDES E, YANNAKOYORGOS K, KALINDERIS A: Sildenafil versus intracavernous injection therapy: efficacy and preference in patients on intracavernous injection for more than 1 year J. Urol. (2000) 164:1197-2000.
13. WYKOWSKI DK AND SWANN J: Use of medications for erectile dysfunction in the United States, 1996 through 2001. J. Urol. (2003) 169:1040-1042.
14. ALTHOF SE: When an erection alone is not enough: biopsychosocial obstacles to lovemaking. Int. Impotence Res. (2002) 14(Suppl. 1):99-104.
15. SOUVEREIN PC, EGBERTS AC, MEULEMAN EJ, URQUHART J, LEUFKENS HG : Incidence and determinants of sildenafil (dis)continuation: the Dutch cohort of sildenafil users. Int. J. Impot. Res. (2002) 14(4):259-265.
16. HACKETT GI, MILLEDGE D: A 12-month follow-up of 260 patients taking sildenafil. NHS clinical experience. In: 4th Congress of the European Society for Sexual and Impotence Research (ESSIR), Rome, 30 September - 3 October 2001 [Poster 171].
17. CASABE A, COBREROS C, BECHARA A, ROLETTO L, CHELIZ G, HOCHMAN S: Drop out reason in responders to sildenafil. Int. J. Impot. Res. (2001) 13(Suppl. 2):S5 [Moderated Poster 9].
18. LEE JC, SURRIDGE DHC, MORALES A, HEATON JPW: Erectile dysfunction: the perspectives of patients and partners on counselling. J. Sex Reprod. Med. (2002) 2:11-15.
19. HATZICHRISTOU DG: Sildenafil failures may be due to inadequate instructions and follow-up: a study on 100 non-responders. Int. J. Impot. Res. (2001) 13:S32 (Abstract 85).
20. HACKET G: What do patients expect from ED therapy. Eur. Urol. (2002) (Suppl. 1):4-11.
21. FRANCIS SH, TURKO IV, CORBIN JD: Cyclic nucleotide phosphodiesterases: relating structure and function. Prog. Nucleic Acid. Res. Mol. Biol. (2001) 65:1-52.
22. VENTER JC, ADAMS MD, MYERS EW et al: The sequence of the human genome. Science (2001) 291:1304-1351.
23. LOUGHNEY K, FERGUSON K: Identification and quantification of PDE isozymes and subtypes by molecular biological methods, In: Phosphodiesterase Inhibitors. Schudt C, Dent G, Rabe KF (Eds), Academic Press, San Diego, USA (1996):1-19.
24. LIN CS, CHOW S, LAU A et al.: Human PDE5A gene encodes three PDE5 isoforms from two alternate promoters. Int. J. Impot. Res. (2002) 14:15-24.
25. BEAVO JA: Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol. Rev. (1995) 75:725-748.
26. HUANG Z, DUCHARME Y, MACDONALD D et al.: The next generation of PDE4 inhibitors. Curr. Opin. Chem. Biol. (200) 15:432-438.
27. LIN CS, XIN ZC, LIN G, LUE TF: Ph:sphodiesterases as therapeutic targets. Urology (2003) 61:685-691.
28. SAENZ DE TEJADA I, GOLDSTEIN I, KRANE RJ: Local control of penile erection. Nerves, smooth muscle and endothelium. Urol. Clin. North Am. (1988) 15:9-16.
29. CARTER AJ, BALLARD SA, AND NAYLOR AM: Effect of the selective phosphodiesterase type 5 inhibitor sildenafil on erectile dysfunction in the anesthetized dog. J. Urol. (1998) 160:242-246.
30. GOLDSTEIN I, LUE TF, PADMA-NATHAN H, ROSEN RC, STEERS WD, WICKER PA: Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. N. Engl. J. Med. (1998) 338:1397-1404.
31. LINCOLN TM: Cyclic GMP and mechanisms of vasodilation. Pharmacol. Ther. (1989) 41:479-502.
32. CARVAJAL JA, GERMAIN AM, HUIDOBRO-TORO JP, WEINER CP: Molecular mechanism of cGMP-mediated smooth muscle relaxation. J. Cell. Physiol. (2000) 184:409-420.
33. IGNARRO LJ, BUSH PA, BUGA GM, WOOD KS, FUKUTO JM, RAJFER J: Nitric oxide and cyclic GMP formation upon electrical field stimulation cause relaxation of corpus cavernosum smooth muscle. Biochem Biophys. Res. Commun. (1990) 170:843-850.
34. PADMA-NATHAN H, MCMURRAY JG, PULLMAN WE et al.: On-demand IC351 (Cialis) enhances erectile function in patients with erectile dysfunction. Int. J. Impot. Res. (2001) 13:2-9.
35. CORBIN JD, FRANCIS SH: Cyclic GMP phosphodiesterase-5: target of sildenafil. J. Biol. Chem. (1999) 274:13729-13732.
36. BAXENDALE RW, SMITH EJ, STANLEY M et al.: Selectivity of sildenafil citrate and other phosphodiesterase Type 5 inhibitors against human PDE types 7-11. Poster, presented at AUA, Anaheim 2001.
37. ANONYMOUS: Scientific discussion on tadalafil. CPMP/3960/02, EMEA (2002).
38. HELLSTROM WJ, OVERSTREET JW, YU A et al.: Tadalafil has no detrimental effect on human spermatogenesis or reproductive hormones. J. Urol. (2003) 170(3):887-891.
39. KUTHE A, WIEDENROTH A, MAGERT HJ et al.: Expression of different phosphodiesterase genes in human cavernous smooth muscle. J. Urol. (2001) 165:280-283.
40. PORST H, PADMA-NATHAN H, GIULIANO F, ANGLIN G, VARANESE L, ROSEN R. Efficacy of tadalafil for the treatment of erectile dysfunction at 24 and 36 h after dosing: a randomized controlled trial. Urology (2003) 62(1):121-125.
41. PATTERSON D, MACDONALD TM, EFFRON MB et al.: Tadalafil does not affect time to ischaemia during exercise stress testing in patients with coronary artery disease. Poster, presented at the 10th World Congress Of The International Society For Sexual And Impotence Research (ISSIR), (2002), Montreal, Canada.
42. HUTTER AM, KLONER RA, WATKINS VS et al.: Poster, presented at the 17th Annual Scientific Meeting of the American Society of Hypertension (ASH), (2002), New York, NY, USA.
43. BROCK GB, MCMAHON CG, CHEN KK et al.: Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analysis. J. Urol. (2002) 168:1332-1336.
44. SAENZ DE TEJADA I, ANGLIN G, KNIGHT JR, EMMICK JT: Effects of tadalafil on erectile dysfunction in men with diabetes. Diabetes Care (2002) 25(12):2159-2164.
45. ROTELLA DP: Tadalafil Lilly ICOS. Curr. Opin. Investig. Drugs (2003) 4(1):60-65.
46. ROSEN RC, RILEY A, WAGNER G, OSTERLOH IH, KIRKPATRICK J, MISHRA A: The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology (1997) 49:822-830.
47. GRESSER U, GLEITER CH: Erectile dysfunction: comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil and tadalafil. Review of the literature. Eur J. Med. Res. (2002) 7:435-446.
48. JUENEMANN KP: Wie wirksam sind die PDE-5 Hemmstoffe. Der Uroge [A] (2003) 42:553-558.
49. PORST H: IC351 (tadalafil, Cialis): update on clinical experience. Int. J. Impot. Res. (2002) 14(Suppl. 1):S57-S64.
50. KANG KK, AHN GJ, AHN BO, YOO M, KIM WB: DA-8159, a new PDE5 inhibitor, induces penile erection in conscious and acute spinal cord injured rabbits. Eur. Urol. (2003) 43:689-695.
51. CHANCELLOR MB, TIRNEY S, MATTES CE et al.: Nitric oxide synthase gene transfer for erectile dysfunction in a rat mosel. BJU Int. (2003) 91:691-696.
52. JACKSON G: Phosphodiesterase type 5 inhibition in cardiovascular disease: experimental models and potential clinical applications. Eur. Heart J. Suppl. (2002) 4(Suppl. H):H19-H23.
53. WYLLIE MG: Pharmaceutical review. The phosphodiesterase inhibitor war. BJU Int. (2003) 91:573-574.